Walgreens Exec: Reimbursement Models Need to Catch Up with GLP-1 Demand
Activity in the GLP-1 medication space is continuing to heat up. On Wednesday, the FDA approved Eli Lilly’s Zepbound as a treatment for weight loss management, which means Novo Nordisk‘s blockbuster drug Wegovy has a new rival. Lilly’s new drug is the same as its type 2 diabetes medication Mounjaro, but it will now be … Read more